Latest Breaking News On - Chinook therapeutics - Page 9 : comparemela.com

Budesonide Reduces eGFR Decline, Effect Could Prevent Clinical Events in IgA Nephropathy

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.

United statesRichard lafayetteJonathan barrattUniversity of leicesterStanford glomerular disease centerAlnylam pharmaceuticalsAmerican society of nephrology kidney weekAmerican societyNephrology kidney weekIgard studyKidney weekMayer professorRenal medicineLeicester generalCalliditas therapeuticsTravere therapeutics

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

Novartis shares positive phase 3 results for atrasentan in rare kidney disease
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Shreeram aradhyeChinook therapeutics

Novartis Pharma AG: Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis Pharma AG: Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMichael meoNicole zinsli sommIhre chancenMarlena abdinoorIndiens wirtschaftRichard jarvisJonathan grahamLambers heerspinkSatoshi sugimotoSamir shahParag mahantiSloan simpsonZain iqbalShreeram aradhyeImke kappes

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial. Treatment with the drug candidate, acquired as part of the purchase of U.S. biotech firm Chinook Therapeutics for up to $3.5 billion, resulted in a clinically meaningful improvement in kidney filtration in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement.

Ludwig burgerFriederike heineDrug administrationChinook therapeuticsKidney functionDrug candidateKidney diseaseDrug trialChinook therapeuticsExperimental drugInterim analysisIdney filtrationRare type

Novartis $3 2B Chinook bet takes flight as phase 3 hits goal

Novartis $3 2B Chinook bet takes flight as phase 3 hits goal
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Chinook therapeutics